Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Cash Flow: 2016-2025

Historic Net Cash Flow for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $25.8 million.

  • Ultragenyx Pharmaceutical's Net Cash Flow rose 107.78% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year decrease of 35.07%. This contributed to the annual value of -$32.7 million for FY2024, which is 140.22% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Net Cash Flow stood at $25.8 million, which was down 44.66% from $46.6 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Net Cash Flow ranged from a high of $368.5 million in Q2 2024 and a low of -$331.3 million during Q3 2024.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Net Cash Flow value was $16.3 million (recorded in 2023), while the average stood at $6.8 million.
  • Examining YoY changes over the last 5 years, Ultragenyx Pharmaceutical's Net Cash Flow showed a top increase of 2,164.18% in 2024 and a maximum decrease of 1,068.89% in 2024.
  • Ultragenyx Pharmaceutical's Net Cash Flow (Quarterly) stood at $100.4 million in 2021, then crashed by 358.92% to -$260.1 million in 2022, then soared by 153.71% to $139.7 million in 2023, then slumped by 81.09% to $26.4 million in 2024, then spiked by 107.78% to $25.8 million in 2025.
  • Its last three reported values are $25.8 million in Q3 2025, $46.6 million for Q2 2025, and -$46.4 million during Q1 2025.